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Abstract
Background: Restart of renal replacement therapy (RRT) af-
ter initial discontinuation of continuous RRT (CRRT) is fre-
quently needed. The aim of the present study was to evalu-
ate whether renal markers after discontinuation of CRRT can 
predict restart of RRT within 90 days. Methods: Prospective 
multicenter observational study in 90 patients, alive, still on 
the intensive care unit at day 2 after discontinuation of CRRT 
for expected recovery with urinary neutrophil gelatinase-as-
sociated lipocalin (NGAL) available. The endpoint was restart 
of RRT within 90 days. Baseline and renal characteristics were 
compared between outcome groups no restart or restart of 
RRT. Logistic regression and receiver operator characteristic 
curve analysis were performed to determine the best predic-
tive and discriminative variables. Results: Restart of RRT was 
needed in 32/90 (36%) patients. Compared to patients not 
restarting, patients restarting RRT demonstrated a higher 
day 2 urinary NGAL, lower day 2 urine output, and higher in-
cremental creatinine ratio (day 2/0). In multivariate analysis, 
only incremental creatinine ratio (day 2/0) remained inde-
pendently associated with restart of RRT (OR 5.28, 95% CI 
1.45–19.31, p = 0.012). The area under curve for incremental 
creatinine ratio to discriminate for restart of RRT was 0.76 
(95% CI 0.64–0.88). The optimal cutoff was 1.49 (95% CI 1.44–
1.62). Conclusion: In this prospective multicenter study, in-
cremental creatinine ratio (day 2/0) was the best predictor 
for restart of RRT. Patients with an incremental creatinine ra-
tio at day 2 of 1.5 times creatinine at discontinuation are like-
ly to need RRT within 90 days. These patients might benefit 
from nephrological follow-up. © 2019 The Author(s) 
Published by S. Karger AG, Basel
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Acute kidney injury (AKI) is a common complication 
of critical illness. If renal replacement therapy (RRT) is 
required, patients have excess mortality even when ad-
justed for severity of disease [1–4]. Among survivors, re-
nal function might not recover and patients may sooner 
or later need chronic RRT. Currently, no clinical charac-
teristics or biomarkers are known to predict restart of 
RRT. Identification of patients at risk and close nephro-
logical follow-up may be important to take preventive 
measures and restart RRT timely. 
Neutrophil gelatinase-associated lipocalin (NGAL) at 
intensive care unit (ICU) admission has high potential as 
predictor for AKI [5–11] and need of continuous RRT 
(CRRT) [9, 12–14]. After renal injury, NGAL is secreted 
into blood and urine within 2 h [15], whereas the rise in 
creatinine takes days. While serum creatinine is a marker 
of renal function, NGAL reflects renal injury. Evaluation 
of NGAL at ICU admission as a predictor for dialysis de-
pendency after an episode of AKI has shown disappoint-
ing results [16, 17]. However, different types of NGAL 
and commercial kits for determination of NGAL are 
available and therefore results might not be comparable. 
Only a few studies evaluated NGAL later during ICU ad-
mission. In patients after out-of-hospital-cardiac-arrest, 
NGAL at day 2–3 was better associated with AKI and 
mortality than NGAL at admission [5, 18]. In sepsis, 
NGAL at day 7 was associated with 28-day mortality [12]. 
However, NGAL after discontinuation of CRRT and its 
association with restart of RRT was not tested. We previ-
ously found that incremental creatinine ratio after dis-
continuation, but not urinary NGAL was independently 
associated with short-term successful discontinuation of 
CRRT (no restart of RRT for 7 days) [19]. However, iden-
tification of the patients at risk for long-term restart is 
also important because these patients need close nephro-
logical follow-up after ICU discharge to take protective 
measures for the kidney, adjust medications, and delay 
restart or prepare the patient for chronic dialysis.
The aim of this study was to evaluate whether urinary 
NGAL, urine output, and incremental creatinine ratio 
measured after discontinuation of CRRT can predict re-
start of RRT within 90 days.
Methods
Study Design
We performed a prospective multicenter observational study 
in 4 ICUs in the Netherlands (additional file 1) to evaluate short-
term (7-day) [19] and long-term (90-day) predictors of restarting 
RRT after initial discontinuation for expected renal recovery. Pa-
tients were included from May 2013 until September 2015. The 
protocol was approved by the medical Ethics Committee of Eras-
mus Medical Centre and local medical Ethical Committees of par-
ticipating centers. Written informed consent was obtained from all 
participants or legal representatives. 
Study Endpoint
The endpoint of study was restart of RRT within 90 days after 
initial discontinuation of CRRT for AKI. 
Patients
All patients, aged 18 years or older, alive and still on the ICU at 
day 2 after discontinuation of CRRT for renal reasons with expected 
renal recovery, excluding patients in whom CRRT was discontinued 
for logistic reasons, such as a CT scan or operation, patients with 
known end-stage renal disease (chronic kidney disease [CKD]-5), 
and those in whom CRRT were discontinued to switch to intermit-
tent hemodialysis, were screened for inclusion. Patients discharged 
from the ICU before day 2 after discontinuation of CRRT were ex-
cluded, because day 2 study variables could not be reliably collected.
Study Protocol and Measurements
The decision to initiate, discontinue, or restart RRT was made 
by the attending team of physicians and was not defined by proto-
col. Reason was that there is no consensus and there are no guide-
lines for restart of RRT. This decision is generally based on a com-
bination of reasons. CRRT was performed according to the local 
protocol of the hospital as CVVH or CVVHD, delivered dose was 
20–35 mL/kg/h. Day 0 was defined as the first 6 a.m. after discon-
tinuation of CRRT. At day 2 after initial discontinuation of CRRT, 
3 renal markers were determined: urinary NGAL, urine output 
and the incremental creatinine ratio between day 2 and 0 (at dis-
continuation; creatinine day 2/0), and the nonrenal sequential or-
gan failure assessment (SOFA) score. The assay for determination 
of urinary NGAL is specified in additional file 1.
We additionally collected: age, sex, weight, BMI, preadmission 
estimated glomerular filtration rate (eGFR; calculated with CKD-
epidemiology collaboration formula [20]), history of CKD and 
other comorbidities, reason for ICU admission, disease severity 
scores (Acute Physiology And Chronic Health Evaluation III, Sim-
plified Acute Physiology Score III), cause of AKI, main reason for 
restart and use of diuretics (day 0–2), radiocontrast agents, or 
nephrotoxic medication (day 0–7). Nephrotoxic medication was 
scored according to the local pharmacological guide, and a list of 
this medication is added in additional file 2. 
Statistical Analysis
Sample size calculation was based on an expected incidence of 
restart of RRT of 30% [21]. To evaluate the prediction of the renal 
markers (urinary NGAL, urine output, and incremental creatinine 
ratio [day 2/0]), we aimed to include 90 patients using the number 
of events/10 rule. Patients not restarting RRT were compared to 
patients restarting temporary or chronic RRT within 90 days. Vari-
ables were tested for normal distribution using the Shapiro-Wilk 
test. Continuous variables are expressed as mean (SD) or median 
(25th and 75th percentile) and categorical data as number and per-
centage. Unpaired Student t test, Mann-Whitney U test, or Chi-
square test was used, where appropriate. Statistical significance 
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was defined as p < 0.05. To assess the relation between renal mark-
ers and other potential predictors of restarting RRT within 90 days, 
univariate analysis was performed. Subsequently, multivariate 
analysis was performed, including the 3 above-defined renal mark-
ers alone, and after adjustment for preadmission eGFR and non-
renal SOFA score. We also performed a sensitivity analysis includ-
ing the patients with missing NGAL concentrations and deter-
mined the relation between the main reasons for restart and the 3 
renal predictors at day 2. For all analyses, multicollinearity was 
checked with a maximum variance inflation factor of 10.
A receiver operator characteristic (ROC) curve was drawn for 
the best discriminative variable for restart of RRT. The area under 
the ROC curve (AUROC) was calculated to discriminate for restart 
of RRT. The Youden index was calculated to determine the opti-
mal cutoff to discriminate for restart of RRT. The 95% CI for the 
optimal cutoff was calculated using bootstrapping with 1,000 ran-
dom samples using the bias corrected and accelerated method.
Results
Of the 254 patients on the ICU at discontinuation of 
CRRT, 90 patients were alive, still at the ICU, and had 
urinary NGAL determined on day 2 after discontinuation 
of CRRT (Fig. 1). Of these 90 patients, 32 (36%) patients 
restarted RRT, while 58 (64%) did not restart RRT within 
90 days after initial discontinuation. Among the 32 pa-
tients restarting RRT, 15/32 only temporary needed RRT, 
whereas 8/32 became dependent of chronic RRT. Nine of 
these 32 patients died after restarting RRT. About 11/32 
patients restarted RRT because of fluid overload, 6/32 re-
started RRT because of oliguria, 14/32 restarted RRT be-
cause of azotemia or a rise in creatinine, and 1/32 restart-
ed RRT because of hyperkalemia. Among the 58 patients 
not restarting RRT 14 patients died within 90 days. The 
clinical course of the 90 study patients and associated 
NGAL concentrations are shown in Figure 2. RRT was 
restarted at a median of 4 (3–10) days, range 2–50. In 
11/32 patients, RRT was restarted > 7 days after discon-
tinuation of CRRT, and in 6/32 patients, RRT was restart-
ed after ICU discharge (range 1–41 days after ICU dis-
charge). The cumulative number of patients restarting 
RRT after initial discontinuation of CRRT is shown in 
Figure 3. In the majority of patients, RRT was restarted 
within 18 days. Among the 148 excluded patients (be-
cause of discharge from the ICU before day 2 after dis-
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continuation of CRRT [n = 98] or because of missing 
NGAL [n = 50]), 45 (30%) restarted RRT within 90 days. 
To assess characteristics of patients restarting RRT, 
this group was compared to patients not restarting RRT 
within 90 days after initial discontinuation of CRRT. 
Characteristics of these groups are presented in Table 1 
and were not different. 
Potential Predictors of Restarting RRT within 90 Days 
after Initial Discontinuation of CRRT
Compared to patients not restarting RRT, patients re-
starting RRT had a higher day 2 urinary NGAL 776 (245–
1,921) vs. 277 (51–670) ng/mL, p = 0.005, a lower day 2 
urine output 1.783 (1.263) vs. 2.503 (1.231) L, p = 0.015 
and higher incremental creatinine ratio (day 2/0) 1.64 
(1.52–1.75) vs. 1.26 (1.01–1.46), p < 0.001. Day 2 nonrenal 
SOFA score and preadmission eGFR were not signifi-
cantly different between groups (Table 2).
Regression Analysis of Potential Predictors of 
Restarting RRT
In univariate regression analysis, we found a signifi-
cant association between restarting RRT within 90 days 
and lower day 2 urine output (OR 0.60, 95% CI 0.39–0.92, 
p = 0.020), higher incremental creatinine ratio (day 2/0; 
OR 5.15, 95% CI 1.42–18.69, p = 0.013), and a trend for 
higher day 2 urinary NGAL (OR 1.00, 95% CI 1.00–1.00, 
p = 0.053; Table 3).
In multivariate regression analysis, only incremen-
tal  creatinine ratio (day 2/0) remained significantly as-
sociated with restarting RRT within 90 days (OR 5.28, 
95% CI 1.45–19.31, p = 0.012; Table 4a). We performed 
a sensitivity analysis also including the patients with 
missing urinary NGAL. Among the 140 patients in 
this  group, 52 patients (37%) restarted RRT, 88 pa-
tients (63%) did not restart RRT. Also in this analysis 
only incremental creatinine ratio (day 2/0) remained 
significantly associated with restarting RRT within 
90 days (OR 5.45, 95% CI 1.87–15.88, p = 0.002; Table 
4b).
Furthermore, we analyzed the association between day 
2 predictors urine output, urinary NGAL, and creatinine 
ratio (day 2/0) stratified per reason for restart of RRT (flu-
id overload, oliguria, azotemia, or creatinine rise and hy-
perkalemia). We only found an independent association 
between restart because of oliguria and day 2 urine output 
(OR 0.040, 95% CI 0.002–0.678, p = 0.026). 
Discrimination of Incremental Creatinine Ratio (Day 
2/0) for Restart of RRT
The AUROC curve for incremental creatinine ratio 
(day 2/0) to discriminate for restart of RRT within 90 days 
was 0.76 (95% CI 0.64–0.88; Fig. 4). The optimal cutoff of 
the incremental creatinine ratio at day 2 to predict restart 
of RRT was 1.49 (95% CI 1.44–1.62), sensitivity 0.79, and 
specificity 0.79.
Day 2
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(n = 58) 64%
NGAL 277 (51–670)
Alive and on the ICU
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Fig. 2. Clinical course of the study patients 
and associated NGAL concentrations. 
NGAL, neutrophil gelatinase-associated li-
pocalin, NGAL results in median (25th–
75th percentile). NGAL is expressed in ng/
mL. ICU, intensive care unit; RRT, renal 
replacement therapy; NGAL, neutrophil 
gelatinase-associated lipocalin.
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Table 1. Patient and disease characteristics of the patients according to restart of RRT within 90 days or not
No restart of
RRT (n = 58)
Restart of
RRT (n = 32) 
p value
Age, years 61 (51–70) 60 (15) 0.610
Gender, male, n (%) 39 (67) 21 (66) 0.876
Weight, kg 81 (14) 83 (19) 0.646
BMI, kg/m2 25.4 (23.1–29.8) 26.6 (5.7) 0.830
History kidney disease, n (%) 11 (19) 11 (34) 0.103
Hypertension, n (%) 19 (33) 9 (28) 0.649
Diabetes mellitus, n (%) 8 (14) 6 (19) 0.535
History of malignancy, n (%) 16 (28) 8 (25) 0.722
History of cardiovascular disease, n (%) 21 (36) 15 (47) 0.323
History of pulmonary disease, n (%) 13 (22) 11 (34) 0.219


































SAPS III at ICU admission 52 (16) 56 (17) 0.313
APACHE III at ICU admission 87 (32) 88 (36) 0.901
Diuretic use day 0–2 44 (76) 25 (81) 0.607
Contrast or nephrotoxic medication day 0–7 54 (93) 28 (88) 0.359
Mean (SD) for normally distributed variables, median (25th–75th percentile) for non-normally distributed 
variables.
BMI, body mass index; ICU, intensive care unit; SAPS III, simplified acute physiology score; APACHE III, 
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Fig. 3. Cumulative number of patients re-







In this prospective multicenter observational study, 
we found that after initial discontinuation of CRRT for 
expected renal recovery, the incremental creatinine ratio 
at day 2 after discontinuation was the only renal marker 
that independently predicted restart of RRT within 90 
days. Urine output and urinary NGAL on day 2 were no 
independent predictors. This association remained after 
adjustment for severity of other organ failure and pread-
mission renal function, which were not related to restart 
of RRT within 90 days. With an AUROC of 0.76, the dis-
crimination of the incremental creatinine ratio (day 2/0) 
was good. A rise of creatinine by one and a half at day 2 
after discontinuation appeared as the optimal cutoff to 
predict restart of RRT within 90 days. 
The main reasons for restart were fluid overload, azo-
temia, or rise in creatinine and oliguria. When analyzing 
whether the reason for restart was associated with one of 
the described predictors, we found that only restart be-
cause of oliguria was associated with urine output at day 
2, while none of the other reasons were associated with 
the day 2 renal predictors. However, the robustness of this 
post hoc analysis can be questioned because subgroups 
were small. Furthermore, we could only analyze the main 
reason for restart, while restart of RRT is generally deter-
mined by a combination of factors. Big data analysis 
would be needed to analyze the different combinations of 
reasons to restart.
The present study shows that two-thirds of the patients 
restarted RRT within the first week after discontinuation 
for expected renal recovery and the majority restarted in 
the first 3 weeks. This finding is in line with previous 
studies [22, 23]. Interestingly, in our short-term restart 
study [19], the incremental creatinine ratio also appeared 
as best predictor for restart within the first week. In that 
study, we found that the incremental creatinine ratio was 
as good as creatinine clearance, of which the measure-
ment is more complex.
Creatinine ratio is presently used to classify the sever-
ity of AKI according to the kidney disease: improving 
global outcomes guidelines during its development [24]. 
In these guidelines, AKI stage 1 is defined as a creatinine 
ratio from 1.5 to 1.9 times baseline. We found that 2 days 
after discontinuation, a creatinine of 1.5 times creatinine 
at discontinuation was the optimal cutoff to predict re-
start of RRT, which is similar to the creatinine ratio used 
to define AKI stage 1. Creatinine ratio after discontinua-
tion of CRRT might therefore be a new and simple tool to 
Table 3. Univariate analysis of potential predictors of restart of 
RRT within 90 days
OR 95% CI p value
Urinary NGAL (day 2), ng/mL 1.00 1.00–1.00 0.053
Urine output (day 2), L 0.60 0.39–0.92 0.020
Creatinine ratio (day 2/0) 5.15 1.42–18.69 0.013
Non-renal SOFA score (day 2) 0.98 0.84–1.15 0.828
Preadmission eGFR 1.00 0.98–1.02 0.883
The ORs are per unit increase.
NGAL is expressed in ng/mL.
RRT, renal replacement therapy; NGAL, neutrophil gelatinase-
associated lipocalin; SOFA, sequential organ failure assessment; 
eGFR, estimated glomerular filtration rate.
Table 2. Comparison of potential predictors according to restart within 90 days or not
No restart of RRT (n = 58) Restart of RRT (n = 32) p value
Study variables
Day 2 urinary NGAL (n = 90), ng/mL 277 (51–670) 776 (245–1,921) 0.005
Day 2 urine output (n = 81), L 2.503 (1.231) 1.783 (1.263) 0.015
Day 2/0 incremental creatinine ratio (n = 81) 1.26 (1.01–1.46) 1.64 (1.52–1.75) <0.001
Confounders
Day 2 nonrenal SOFA (n = 82) 4 (2–6) 5 (3) 0.883
Preadmission eGFR (CKD-EPI; n = 85), mL/min/1.73 m2 67.1 (25.4) 69.0 (41.2–91.7) 0.754
Median (25th–75th percentile) for continuous variables, number (percentage) when appropriate.
NGAL is expressed in ng/mL.
RRT, renal replacement therapy; NGAL, neutrophil gelatinase-associated lipocalin; SOFA, sequential organ failure assessment; 
eGFR, estimated glomerular filtration rate; CKD-EPI, chronic kidney disease-epidemiology collaboration.
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identify patients at risk for further renal function deterio-
ration and thus for nephrological follow-up. 
Unexpectedly, we found no independent association 
between day 2 urinary NGAL and restart of RRT within 
90 days. Although median NGAL concentrations were 
significantly higher in patients restarting RRT compared 
to patients not restarting RRT, significance was lost when 
conventional markers of renal function were included in 
the analysis. Of interest, we found that neither for short-
term (within 7 days) [19] nor for long-term restart, NGAL 
was independently predictive of restart. This finding is 
unexpected and has not been reported before in the lit-
erature. As mentioned before, urinary NGAL determined 
at ICU admission is an early marker of renal injury and 
associated with development of AKI and need of CRRT 
[5–15]. Previous studies found a poor association be-
tween NGAL on admission and late major adverse kidney 
events [17, 25]. However, none of these studies deter-
mined NGAL after discontinuation of CRRT. We dem-
onstrated that the renal injury marker urinary NGAL af-
ter discontinuation of CRRT was also not independently 
associated with restart of RRT. In contrast, the incremen-
tal creatinine ratio, a simple renal function marker, was 
the best predictor. Accordingly, the more complex renal 
function marker kinetic eGFR also was a better predictor 
of late major adverse kidney events than urinary NGAL 
[16]. It therefore seems that after discontinuation of 
CRRT for expected recovery, the remaining renal func-
tion is more important to predict whether the kidney will 
recover without restarting RRT than the renal damage 
marker NGAL, which better predicts the development of 
AKI. 
Another remarkable result was that preadmission 
eGFR was not significantly different between patients re-
Table 4.
a Multivariate analysis of variables associated with restart of RRT within 90 days (n = 90)
OR 95% CI p value
Step 1
Urinary NGAL (day 2) 1.00 1.00–1.00 0.724
Urine output (day 2) 0.77 0.47–1.25 0.286
Creatinine ratio (day 2/0) 3.94 1.03–15.00 0.045
Step 2
Urine output (day 2) 0.75 0.47–1.19 0.221
Creatinine ratio (day 2/0) 4.05 1.06–15.41 0.040
Step 3
Creatinine ratio (day 2/0) 5.28 1.45–19.31 0.012
The ORs are per unit increase. Variables included: primary analysis: urinary NGAL (day 2), urine output (day 
2), creatinine ratio (day 2/0) as confounders: preadmission eGFR, nonrenal SOFA score (day 2).
RRT, renal replacement therapy; NGAL, neutrophil gelatinase-associated lipocalin; SOFA, sequential organ 
failure assessment.
b Multivariate sensitivity analysis of variables associated with restart of RRT within 90 days including the pa-
tients with missing NGAL (n = 140)
OR 95% CI p value
Step 1
Urine output (day 2) 0.79 0.53–1.19 0.258
Creatinine ratio (day 2/0) 4.36 1.43–13.33 0.010
Step 2
Creatinine ratio (day 2/0) 5.45 1.87–15.88 0.002
The ORs are per unit increase. Variables included: primary analysis: urine output (day 2), creatinine ratio (day 
2/0) as confounders: preadmission eGFR, non-renal SOFA score (day 2).
RRT, renal replacement therapy; NGAL, neutrophil gelatinase-associated lipocalin; eGFR, estimated glomer-





starting and patients not restarting RRT. This is in seem-
ing contrast to results found in previous studies in which 
acute on CKD was  a major risk factor for end-stage renal 
disease [21, 26]. However, we excluded patients with end-
stage renal disease (CKD 5) and patients in whom CRRT 
was discontinued to switch to intermittent hemodialysis. 
Thus, patients with the worst preadmission renal func-
tion were excluded. This may explain why preadmission 
eGFR did not differ between the need of RRT groups in 
our cohort. Independent of CKD, severe AKI, that is, AKI 
requiring RRT is a risk factor for incomplete renal recov-
ery and for the development of subsequent end-stage re-
nal disease and chronic dialysis [27, 28]. However, in our 
cohort, all included patients had severe AKI because only 
patients with AKI requiring RRT were included.
Several studies evaluated predictors of restart of RRT 
or dialysis dependency after AKI. Some studies evaluated 
risk factors at initiation of CRRT: age, CKD, comorbidi-
ties, and severity of disease [21, 26, 29]. Five studies eval-
uated renal markers at discontinuation and found urine 
output, 2-h creatinine clearance, and 24-h urinary creati-
nine excretion as predictors of successful discontinuation 
[22, 23, 30–32]. In contrast to the present study, these 
studies evaluated short-term successful discontinuation 
(3–15 days). These studies were retrospective in design, 
included selected populations, such as only surgical pa-
tients, and used different modalities of RRT, such as 
CRRT and intermittent hemodialysis [22, 23, 30–32]. 
None of these studies evaluated delta creatinine as a pre-
dictor. The present prospective study suggests that an in-
cremental creatinine ratio of 1.5 or more 2 days after dis-
continuation would be a practical trigger to consult the 
nephrologist for follow-up. 
Nowadays, only about 8.5% of patients at risk for fur-
ther renal function deterioration after an episode of AKI 
receive referral to a nephrologist. However, mortality and 
incidence of end-stage renal disease in this population is 
high (22%) [33]. In our cohort, 6/32 patients (19%) re-
started RRT after ICU discharge, especially these patients 
could benefit from nephrological follow-up, but possibly 
also those restarting RRT in the ICU. Previous studies 
found that early nephrological follow-up after an episode 
of AKI is associated with improved survival [34]. The kid-
ney disease: improving global outcomes guidelines al-
ready recommend supportive measures in patients at 
high risk for AKI or CKD [35]. Therefore, it may be ben-
eficial if intensivists and nephrologists cooperate early af-
ter discontinuation of CRRT to determine optimal hemo-
dynamic conditions, dose pharmacotherapy thereby re-
ducing potential nephrotoxic events. Thus, the 
determination of risk factors for restart of RRT early after 
discontinuation seems important. 
Our study has some limitations. First, a large number of 
patients were excluded because of discharge before day 2 
after discontinuation of CRRT or missing NGAL. This 
might have caused bias; however, these patients had similar 
rates of restart, and in the multivariate sensitivity analysis, 
incremental creatinine ratio also was the only independent 
predictor. Furthermore, we evaluated the renal markers at 
day 2 after discontinuation and not at day 1. The reason was 
that we aimed to include only patients in whom CRRT was 
discontinued because of expected recovery of renal func-
tion, and we did not want to include patients in whom 
CRRT was temporarily discontinued because of logistic 
reasons, such as a CT scan or operation. Furthermore, we 
evaluated the incremental creatinine ratio day 2/0, because 
we supposed that the creatinine ratio day 1/0 might not 
have been discriminative enough. This was later on also 
found in another study [16]. Second, death might be a com-
peting endpoint. Patients who died within 90 days could 
have needed RRT if still alive. We therefore presented the 
NGAL data in all different subgroups. Patients restarting 
RRT seemed to have higher NGAL concentrations than 
those who died without receiving RRT. Third, patients 
who switched directly from CRRT to intermittent hemo-
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Fig. 4. ROC curve of creatinine ratio (day 2/0) for discrimination 
of restart of RRT within 90 days. AUC, area under the curve.
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was not discontinued because of expected recovery, but for 
change of RRT modality and they therefore did not fulfill 
the inclusion criteria. Fourth, restart of RRT was not pro-
tocolized, and the attending physician decided whether 
RRT was restarted. Therefore, reasons for restart might be 
different between centers. However, there is currently no 
consensus on criteria, and there are no guidelines describ-
ing criteria for restart of RRT. Thus, our study describes 
current practice in 4 Dutch hospitals. 
Our study has several strengths. First, we performed a 
multicenter study, including ICU patients in 4 hospitals, 
including an academic hospital; hence, our results are 
highly generalizable. Further, to our knowledge, this is 
the first prospective study determining predictors for re-
start of RRT after discontinuation of CRRT, which allows 
the attending physician to select patients who might es-
pecially benefit from nephrological follow-up. Finally, 
creatinine ratio is a simple marker, which is already used 
to stage developing AKI and therefore well-known and 
available in clinical practice.
Conclusions 
In this prospective multicenter study, in patients alive 
and still on the ICU at day 2 after discontinuation of 
CRRT, the incremental creatinine ratio at day 2 after dis-
continuation predicted restart of RRT within 90 days, in-
dependent of urinary NGAL, urinary output, preadmis-
sion eGFR, and severity of organ failure. The present 
study suggests that when the rise in creatinine at day 2 
after discontinuation of CRRT is 1.5 or more, the patient 
will likely need restart of RRT within 90 days. We hereby 
provide a simple and useful tool to select patients who 
might benefit from nephrological follow-up. 
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